Health Catalyst (HCAT) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

HCAT Stock Forecast

Health Catalyst stock forecast is as follows: an average price target of $9.67 (represents a 36.39% upside from HCAT’s last price of $7.09) and a rating consensus of 'Buy', based on 16 wall street analysts offering a 1-year stock forecast.

HCAT Price Target

The average price target for Health Catalyst (HCAT) is $9.67 based on 1-year price targets from 16 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $7.00. This represents a potential 36.39% upside from HCAT's last price of $7.09.

HCAT Analyst Ratings

Buy

According to 16 Wall Street analysts, Health Catalyst's rating consensus is 'Buy'. The analyst rating breakdown for HCAT stock is 0 'Strong Buy' (0.00%), 11 'Buy' (68.75%), 5 'Hold' (31.25%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Health Catalyst Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 03, 2024	Richard Close	Canaccord Genuity	$11.00	$7.29	50.89%	55.15%
Aug 26, 2024	Jessica Tassan	Piper Sandler	$11.00	$7.19	52.99%	55.15%
Aug 08, 2024	Jeff Garro	Stephens	$7.00	$5.48	27.74%	-1.27%
Jun 06, 2024	Jessica Tassan	Piper Sandler	$14.00	$6.70	108.96%	97.46%
Jan 26, 2024	Jack Wallace	Guggenheim	$14.00	$9.94	40.85%	97.46%
May 11, 2022	Jessica Tassan	Piper Sandler	$21.00	$12.95	62.16%	196.19%
Mar 02, 2022	Elizabeth Anderson CFA	Evercore ISI	$48.00	$27.54	74.29%	577.01%
Mar 02, 2022	Sean Dodge	RBC Capital	$35.00	$27.54	27.09%	393.65%
Feb 11, 2022	Cindy Motz CFA	Goldman Sachs	$48.00	$30.14	59.26%	577.01%
May 27, 2021	Sandy Draper	Guggenheim	$60.00	$54.25	10.60%	746.26%
May 07, 2021	Steven Halper	Cantor Fitzgerald	$60.00	$53.23	12.72%	746.26%

The latest Health Catalyst stock forecast, released on Sep 03, 2024 by Richard Close from Canaccord Genuity, set a price target of $11.00, which represents a 50.89% increase from the stock price at the time of the forecast ($7.29), and a 55.15% increase from HCAT last price ($7.09).

Health Catalyst Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	5
Avg Price Target	-	-	$11.40
Last Closing Price	$7.09	$7.09	$7.09
Upside/Downside	-100.00%	-100.00%	60.79%

In the current month, the average price target of Health Catalyst stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Health Catalyst's last price of $7.09. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 08, 2024	Evercore ISI	Outperform	Outperform	Hold
Sep 20, 2024	Stephens	Equal-Weight	Equal-Weight	Hold
Sep 20, 2024	Raymond James	Underperform	Underperform	Hold
Sep 03, 2024	Canaccord Genuity	Buy	Buy	Hold
Aug 26, 2024	Piper Sandler	Overweight	Overweight	Hold
Aug 09, 2024	Stephens	Buy	Buy	Hold
Aug 09, 2024	Piper Sandler	Underperform	Underperform	Hold
Aug 08, 2024	Stephens	Equal-Weight	Equal-Weight	Hold
Jul 09, 2024	Wells Fargo	Buy	Buy	Hold
Jul 09, 2024	Piper Sandler	Underperform	Underperform	Hold
Jul 01, 2024	Wells Fargo	Overweight	Overweight	Hold
Jun 06, 2024	Citigroup	Buy	Buy	Hold
Jun 06, 2024	Piper Sandler	Underperform	Underperform	Hold
Jun 06, 2024	Piper Sandler	Overweight	Overweight	Hold
May 21, 2024	Raymond James	Underperform	Underperform	Hold
May 21, 2024	Wells Fargo	Buy	Buy	Hold
Apr 10, 2024	KeyBanc	Overweight	Sector Weight	Downgrade
Jan 26, 2024	Guggenheim		Buy	Upgrade
Dec 13, 2023	Barclays		Overweight	Upgrade
Nov 13, 2023	Piper Sandler	Neutral	Overweight	Upgrade
Aug 01, 2023	Cantor Fitzgerald		Overweight	Initialise
Aug 01, 2023	Morgan Stanley		Equal-Weight	Initialise
Aug 01, 2023	Seaport Global		Buy	Initialise
May 10, 2023	William Blair	Outperform	Outperform	Hold
Apr 20, 2023	Wells Fargo	Overweight	Underweight	Initialise
Apr 20, 2023	KeyBanc		Overweight	Upgrade
Apr 04, 2023	Benchmark		Hold	Initialise
Apr 04, 2023	Wells Fargo		Overweight	Upgrade
Sep 13, 2022	Piper Sandler		Neutral	Downgrade
Aug 05, 2022	SVB Leerink		Neutral	Downgrade
Mar 02, 2022	RBC Capital	Outperform	Outperform	Hold

Health Catalyst's last stock rating was published by Evercore ISI on Oct 08, 2024. The company gave HCAT a "Outperform" rating, the same as its previous rate.

Health Catalyst Financial Forecast

Health Catalyst Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$73.77M	$73.21M	$73.87M	$69.16M	$68.35M	$70.63M	$68.09M	$64.72M	$61.74M	$59.63M	$55.85M	$53.28M	$47.19M	$43.26M	$45.12M	$43.50M	$39.42M
Avg Forecast	$100.35M	$95.25M	$94.31M	$92.93M	$89.03M	$85.06M	$84.16M	$83.00M	$80.68M	$76.27M	$74.96M	$74.82M	$73.57M	$73.04M	$72.64M	$71.24M	$68.26M	$66.82M	$69.88M	$66.01M	$63.12M	$60.81M	$56.60M	$54.30M	$52.04M	$44.60M	$42.29M	$43.47M	$41.76M	$37.74M
High Forecast	$101.67M	$96.51M	$95.55M	$94.15M	$90.20M	$86.18M	$85.26M	$83.80M	$81.18M	$76.38M	$74.96M	$74.82M	$74.50M	$73.89M	$73.59M	$72.18M	$69.16M	$66.82M	$69.88M	$66.01M	$63.12M	$60.81M	$56.60M	$54.30M	$52.04M	$44.60M	$42.29M	$43.47M	$41.76M	$37.74M
Low Forecast	$98.78M	$93.76M	$92.83M	$91.48M	$87.64M	$83.73M	$82.84M	$82.19M	$80.13M	$76.15M	$74.96M	$74.82M	$72.88M	$72.01M	$71.50M	$70.12M	$67.19M	$66.82M	$69.88M	$66.01M	$63.12M	$60.81M	$56.60M	$54.30M	$52.04M	$44.60M	$42.29M	$43.47M	$41.76M	$37.74M
# Analysts	4	4	4	4	3	3	3	5	9	4	3	3	6	14	13	7	6	6	8	6	7	11	7	13	13	7	7	9	8	6
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.01%	1.01%	1.04%	1.01%	1.02%	1.01%	1.03%	1.03%	1.02%	1.05%	1.03%	1.02%	1.06%	1.02%	1.04%	1.04%	1.04%

Health Catalyst's average Quarter revenue forecast for Dec 23 based on 6 analysts is $73.57M, with a low forecast of $72.88M, and a high forecast of $74.50M. HCAT's average Quarter revenue forecast represents a -0.27% decrease compared to the company's last Quarter revenue of $73.77M (Sep 23).

Health Catalyst EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	9	4	3	3	6	14	13	7	6	6	8	6	7	11	7	13	13	7	7	9	8	6
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-14.39M	$-19.70M	$-23.92M	$-25.08M	$-33.35M	$-19.95M	$-12.55M	$-42.59M	$-31.56M	$-23.72M	$-16.32M	$9.81M	$-18.12M	$-20.38M	$-14.24M	$-10.16M	$-17.43M
Avg Forecast	$-33.17M	$-31.49M	$-31.18M	$-30.72M	$-29.43M	$-28.12M	$-27.82M	$-27.44M	$-26.67M	$-25.21M	$-24.78M	$-19.89M	$-24.32M	$-24.15M	$-24.01M	$-18.08M	$12.49M	$-21.54M	$-22.53M	$-16.44M	$-20.35M	$-19.61M	$-18.25M	$-23.51M	$-16.78M	$-14.38M	$-13.64M	$-19.37M	$-13.46M	$-12.17M
High Forecast	$-32.65M	$-31.00M	$-30.69M	$-30.24M	$-28.97M	$-27.68M	$-27.39M	$-27.17M	$-26.49M	$-25.18M	$-24.78M	$-15.91M	$-24.09M	$-23.80M	$-23.64M	$-14.46M	$14.99M	$-21.54M	$-22.53M	$-13.15M	$-20.35M	$-19.61M	$-18.25M	$-18.81M	$-16.78M	$-14.38M	$-13.64M	$-15.50M	$-13.46M	$-12.17M
Low Forecast	$-33.61M	$-31.90M	$-31.59M	$-31.13M	$-29.82M	$-28.49M	$-28.19M	$-27.70M	$-26.84M	$-25.25M	$-24.78M	$-23.86M	$-24.63M	$-24.43M	$-24.33M	$-21.70M	$9.99M	$-21.54M	$-22.53M	$-19.72M	$-20.35M	$-19.61M	$-18.25M	$-28.21M	$-16.78M	$-14.38M	$-13.64M	$-23.25M	$-13.46M	$-12.17M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.60%	0.82%	1.32%	-2.01%	1.55%	0.89%	0.76%	2.09%	1.61%	1.30%	0.69%	-0.58%	1.26%	1.49%	0.74%	0.76%	1.43%

13 analysts predict HCAT's average Quarter EBITDA for Mar 21 to be $-23.51M, with a high of $-18.81M and a low of $-28.21M. This is -339.73% lower than Health Catalyst's previous annual EBITDA (Dec 20) of $9.81M.

Health Catalyst Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	9	4	3	3	6	14	13	7	6	6	8	6	7	11	7	13	13	7	7	9	8	6
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-22.03M	$-32.61M	$-33.19M	$-35.78M	$-45.73M	$-33.43M	$-22.46M	$-48.99M	$-40.01M	$-35.83M	$-28.37M	$-43.02K	$-27.33M	$-27.18M	$-17.49M	$-14.27M	$-21.42M
Avg Forecast	$9.67M	$8.92M	$8.76M	$7.25M	$5.84M	$5.02M	$5.20M	$4.72M	$4.38M	$5.83M	$4.84M	$-35.57M	$708.73K	$-168.03K	$-649.80K	$-32.34M	$-54.79K	$-11.25M	$-5.66M	$-29.40M	$-12.56M	$-12.89M	$-8.12M	$-40.85M	$-11.75M	$-15.83M	$-14.02M	$-23.79M	$-17.20M	$-21.60M
High Forecast	$9.84M	$9.07M	$8.91M	$7.38M	$5.94M	$5.11M	$5.29M	$4.80M	$5.05M	$5.97M	$4.84M	$-28.46M	$7.80M	$420.06K	$-636.58K	$-25.87M	$-43.83K	$-11.25M	$-5.66M	$-23.52M	$-12.56M	$-12.89M	$-8.12M	$-32.68M	$-11.75M	$-15.83M	$-14.02M	$-19.03M	$-17.20M	$-21.60M
Low Forecast	$9.47M	$8.73M	$8.59M	$7.11M	$5.72M	$4.92M	$5.10M	$4.63M	$3.37M	$5.69M	$4.84M	$-42.69M	$-1.42M	$-1.09M	$-660.91K	$-38.81M	$-65.75K	$-11.25M	$-5.66M	$-35.28M	$-12.56M	$-12.89M	$-8.12M	$-49.02M	$-11.75M	$-15.83M	$-14.02M	$-28.54M	$-17.20M	$-21.60M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	131.12%	50.19%	1.03%	653.08%	4.07%	5.91%	0.76%	3.90%	3.10%	4.42%	0.69%	0.00%	1.73%	1.94%	0.74%	0.83%	0.99%

Health Catalyst's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. HCAT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Health Catalyst SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	9	4	3	3	6	14	13	7	6	6	8	6	7	11	7	13	13	7	7	9	8	6
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$28.71M	$40.07M	$42.40M	$36.52M	$44.59M	$38.46M	$29.64M	$47.20M	$43.86M	$39.23M	$30.67M	$42.92M	$27.93M	$20.61M	$23.19M	$20.09M	$25.73M
Avg Forecast	$56.37M	$53.51M	$52.98M	$52.20M	$50.01M	$47.78M	$47.27M	$46.62M	$45.32M	$42.84M	$42.11M	$46.95M	$41.33M	$41.03M	$40.80M	$42.68M	$54.67M	$36.00M	$37.65M	$38.80M	$34.01M	$32.76M	$30.49M	$44.16M	$28.03M	$24.03M	$22.78M	$31.54M	$22.50M	$20.33M
High Forecast	$57.11M	$54.21M	$53.67M	$52.89M	$50.67M	$48.41M	$47.90M	$47.07M	$45.60M	$42.90M	$42.11M	$56.34M	$41.85M	$41.51M	$41.34M	$51.22M	$65.60M	$36.00M	$37.65M	$46.56M	$34.01M	$32.76M	$30.49M	$52.99M	$28.03M	$24.03M	$22.78M	$37.84M	$22.50M	$20.33M
Low Forecast	$55.49M	$52.67M	$52.15M	$51.39M	$49.23M	$47.04M	$46.53M	$46.17M	$45.01M	$42.78M	$42.11M	$37.56M	$40.94M	$40.45M	$40.16M	$34.15M	$43.74M	$36.00M	$37.65M	$31.04M	$34.01M	$32.76M	$30.49M	$35.33M	$28.03M	$24.03M	$22.78M	$25.23M	$22.50M	$20.33M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.70%	0.98%	0.99%	0.67%	1.24%	1.02%	0.76%	1.39%	1.34%	1.29%	0.69%	1.53%	1.16%	0.90%	0.74%	0.89%	1.27%

Health Catalyst's average Quarter SG&A projection for Dec 23 is $41.33M, based on 6 Wall Street analysts, with a range of $40.94M to $41.85M. The forecast indicates a 43.95% rise compared to HCAT last annual SG&A of $28.71M (Sep 23).

Health Catalyst EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	9	4	3	3	6	14	13	7	6	6	8	6	7	11	7	13	13	7	7	9	8	6
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.39	$-0.58	$-0.60	$-0.66	$-0.84	$-0.62	$-0.42	$-0.94	$-0.82	$-0.80	$-0.65	$-0.00	$-0.68	$-0.71	$-0.47	$-0.39	$-0.76
Avg Forecast	$0.16	$0.15	$0.14	$0.12	$0.10	$0.08	$0.09	$0.08	$0.07	$0.10	$0.08	$0.03	$0.01	$-0.00	$-0.01	$-0.04	$-0.11	$-0.19	$-0.10	$-0.11	$-0.21	$-0.22	$-0.14	$-0.17	$-0.20	$-0.27	$-0.24	$-0.25	$-0.29	$-0.36
High Forecast	$0.16	$0.15	$0.15	$0.12	$0.10	$0.08	$0.09	$0.08	$0.08	$0.10	$0.08	$0.03	$0.13	$0.01	$-0.01	$-0.04	$-0.11	$-0.19	$-0.10	$-0.11	$-0.21	$-0.22	$-0.14	$-0.17	$-0.20	$-0.27	$-0.24	$-0.25	$-0.29	$-0.36
Low Forecast	$0.16	$0.14	$0.14	$0.12	$0.09	$0.08	$0.08	$0.08	$0.06	$0.09	$0.08	$0.03	$-0.02	$-0.02	$-0.01	$-0.04	$-0.11	$-0.19	$-0.10	$-0.11	$-0.21	$-0.22	$-0.14	$-0.17	$-0.20	$-0.27	$-0.24	$-0.25	$-0.29	$-0.36
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	140.29%	53.95%	16.31%	5.89%	4.43%	6.50%	3.92%	4.44%	3.77%	5.85%	3.82%	0.01%	2.55%	3.00%	1.86%	1.34%	2.08%

According to undefined Wall Street analysts, Health Catalyst's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to HCAT previous annual EPS of $NaN (undefined).

Health Catalyst Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
EVH	Evolent Health	$10.87	$33.00	203.59%	Buy
FORA	Forian	$2.04	$4.50	120.59%	Buy
SLP	Simulations Plus	$30.04	$47.00	56.46%	Buy
DH	Definitive Healthcare	$4.46	$6.08	36.32%	Hold
CERT	Certara	$11.40	$15.00	31.58%	Buy
HCAT	Health Catalyst	$7.65	$9.67	26.41%	Buy
HQY	HealthEquity	$91.09	$108.33	18.93%	Buy
PRVA	Privia Health Group	$20.79	$23.00	10.63%	Buy
PINC	Premier	$21.17	$20.00	-5.53%	Hold
HSTM	HealthStream	$31.97	$29.00	-9.29%	Buy

HCAT Forecast FAQ

Is Health Catalyst a good buy?

Yes, according to 16 Wall Street analysts, Health Catalyst (HCAT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 68.75% of HCAT's total ratings.

What is HCAT's price target?

Health Catalyst (HCAT) average price target is $9.67 with a range of $7 to $11, implying a 36.39% from its last price of $7.09. The data is based on 16 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Health Catalyst stock go up soon?

According to Wall Street analysts' prediction for HCAT stock, the company can go up by 36.39% (from the last price of $7.09 to the average price target of $9.67), up by 55.15% based on the highest stock price target, and down by -1.27% based on the lowest stock price target.

Can Health Catalyst stock reach $11?

HCAT's average twelve months analyst stock price target of $9.67 does not support the claim that Health Catalyst can reach $11 in the near future.

What are Health Catalyst's analysts' financial forecasts?

Health Catalyst's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $341.25M (high $345.45M, low $336.4M), average EBITDA is $-113M (high $-111M, low $-114M), average net income is $20.79M (high $21.15M, low $20.37M), average SG&A $191.69M (high $194.05M, low $188.97M), and average EPS is $0.344 (high $0.35, low $0.337). HCAT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $382.84M (high $387.88M, low $376.85M), average EBITDA is $-127M (high $-125M, low $-128M), average net income is $34.6M (high $35.19M, low $33.9M), average SG&A $215.06M (high $217.88M, low $211.69M), and average EPS is $0.573 (high $0.582, low $0.561).

Did the HCAT's actual financial results beat the analysts' financial forecasts?

Based on Health Catalyst's last annual report (Dec 2022), the company's revenue was $276.24M, beating the average analysts forecast of $270.96M by 1.95%. Apple's EBITDA was $-91.708M, beating the average prediction of $-48.02M by 90.98%. The company's net income was $-137M, beating the average estimation of $-46.356M by 196.41%. Apple's SG&A was $149.22M, missing the average forecast of $167.11M by -10.71%. Lastly, the company's EPS was $-2.56, beating the average prediction of $-0.504 by 407.85%. In terms of the last quarterly report (Sep 2023), Health Catalyst's revenue was $73.77M, beating the average analysts' forecast of $73.04M by 1.00%. The company's EBITDA was $-14.39M, missing the average prediction of $-24.147M by -40.41%. Health Catalyst's net income was $-22.032M, beating the average estimation of $-168K by 13012.33%. The company's SG&A was $28.71M, missing the average forecast of $41.03M by -30.03%. Lastly, the company's EPS was $-0.39, beating the average prediction of $-0.00278 by 13928.78%